Evidence map›Paper›PMID 28801790›Full record

ReviewCurrent cardiology reports2017

Cardiovascular Disease, the Nitric Oxide Pathway and Risk of Cognitive Impairment and Dementia.

Blossom C M Stephan, Stephanie L Harrison, Hannah A D Keage, Abrar Babateen, Louise Robinson, Mario Siervo

Abstract readReview
In one paragraph

Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Blossom C M StephanInstitute of Health and Society and Newcastle University Institute for Ageing, Newcastle University, Newcastle Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne,, NE4 5PL, UK. blossom.stephan@ncl.ac.uk.
Stephanie L HarrisonDepartment of Rehabilitation, Aged and Extended Care, Faculty of Medicine, Nursing and Health Sciences, School of Health Sciences, Flinders University, Adelaide, Australia.
Hannah A D KeageCognitive Ageing and Impairment Neurosciences Laboratory, School of Psychology, Social Work and Social Policy, University of South Australia, Adelaide, Australia.
Abrar BabateenInstitute of Cellular Medicine, Newcastle University, Newcastle Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne,, NE4 5PL, UK.
Louise RobinsonInstitute of Health and Society and Newcastle University Institute for Ageing, Newcastle University, Newcastle Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne,, NE4 5PL, UK.
Mario SiervoInstitute of Cellular Medicine, Newcastle University, Newcastle Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne,, NE4 5PL, UK.

Funding

Department of Health NIHR-RP-011-043Medical Research Council MR/N007921/1
6 · The paper itself

Abstract

purpose of reviewIn this review, we summarise the evidence on the association between cardiovascular disease (CVD) and cognitive impairment and explore the role of the nitric oxide (NO) pathway as a causal mechanism. RECENT

findingsEvidence from epidemiological studies suggests that the presence of CVD and its risk factors in midlife is associated with an increased risk of later life cognitive impairment and dementia. It is unclear what is driving this association but risk may be conveyed via an increase in neurodegeneration (e.g. amyloid deposition), vascular changes (e.g. small vessel disease) and mechanistically due to increased levels of oxidative stress and inflammation as well as changes in NO bioavailability. CVDs and dementia are major challenges to global health worldwide. The NO pathway may be a promising biological candidate for future studies focused on reducing not only CVD but also risk of cognitive decline and dementia.

Indexed as

Age FactorsCardiovascular DiseasesCognition DisordersCognitive DysfunctionDementiaHumansInflammationNitric OxideOxidative StressRisk FactorsNitric OxideCardiovascular diseaseCognitive impairmentDementiaEndothelial functionNitric oxide

Identifiers

PMID28801790
PMCPMC5554286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.